NEW YORK, July 11 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX), Forest Laboratories Holdings, Ltd. and H. Lundbeck A/S
announced that they have filed a lawsuit in the U.S. District Court for the
Eastern District of Michigan against Caraco Pharmaceutical Laboratories,
Ltd. for infringement of U.S. Patent Re. No. 34,712, which relates to
Forest's Lexapro(R) product.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
Forest has received notification from Caraco Pharmaceutical
Laboratories, Ltd. that it filed an Abbreviated New Drug Application (ANDA)
with a Paragraph IV Certification for a generic equivalent to Lexapro(R).
Howard Solomon, Chairman and Chief Executive Officer of Forest, said:
"We believe the patent on Lexapro is valid and enforceable. Just as we did
in our prior patent litigations against Ivax Pharmaceuticals and
Alphapharm, we intend to prosecute this lawsuit vigorously."
Except for the historical information contained herein, this release
contains "forward-looking statements" within the meaning of the Private
Securities Reform Act of 1995. These statements involve a number of risks
and uncertainties, including the difficulty of predicting FDA approvals,
the acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in the Forest
Laboratories' SEC reports, including the Company's Annual Report on Form
10-K for the fiscal year ended March 31, 2006.
SOURCE Forest Laboratories, Inc.
 back to top
Related links:
http://www.frx.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
CONTACT:
Charles E. Triano, Vice President-Investor
Relations of Forest Laboratories, Inc., +1-212-224-6714,
charles.triano@frx.com
|
